6 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Terminated 6 |
Follow Endocarditis: new trials by email Literature Review of Endocarditis trials Research Report on Endocarditis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis | Phase 4 | Terminated | West Virginia University | 5 | 2022-03-16 | 2026-05-05 |
| Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Antibiotics - Endocarditis, Bacterial | Phase 4 | Terminated | Carmen Olmos Blanco | 20 | 2021-01-26 | 2023-09-28 |
| An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures Amoxicillin, Amoxicillin-Potassium Clavulanate - Bacteraemia, Endocarditis | Phase 4 | Terminated | University of Santiago de Compostela | 40 | 2017-02-27 | 2022-05-24 |
| Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Vancomycin, Ceftaroline, Daptomycin - Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis | Phase 4 | Terminated | Henry Ford Health System | 100 | 2011-10-01 | 2023-05-03 |
| Phase 4 Efficacy and Safety Study of CubicinĀ® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) daptomycin, daptomycin and gentamicin - Infective Endocarditis | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 24 | 2009-02-13 | 2021-02-02 |
| Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. Daptomycin - Endocarditis, Bacterial | Phase 4 | Terminated | Weill Medical College of Cornell University | 6 | 2006-09-01 | 2017-05-03 |
Bacteremia (2) · Endocarditis, Bacterial (2) · Arthritis, Infectious (1) · Gram-Positive Bacterial Infections (1) · Osteomyelitis (1) · Staphylococcal Infections (1) · Toxemia (1)
Cardiovascular Diseases (6) · Heart Diseases (6) · Infections (5) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Cardiovascular Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Sepsis (2) · Systemic Inflammatory Response Syndrome (2) · Arthritis (1) · Bone Diseases (1) · Bone Diseases, Infectious (1) · Joint Diseases (1)
Daptomycin (4) · Amoxicillin (2) · Ceftaroline (2) · Linezolid (2) · Vancomycin (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Ampicillin (1) · Anti-Bacterial Agents (1) · Cefepime (1) · Ceftriaxone (1) · Cephalexin (1) · Dicloxacillin (1) · Drugs, Generic (1) · Gentamicins (1) · Injections (1)
Carmen Olmos Blanco (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Henry Ford Health System (1) · University of Santiago de Compostela (1) · Weill Medical College of Cornell University (1) · West Virginia University (1)
United States (4) · Spain (2)
Jose Vazquez, M.D. (1) · Kyu Y Rhee, MD, PhD (1) · Paula Bokesch, M.D. (1) · Pedro Diz, MD, DDS, PhD (1) · Vinay Badhwar, MD (1)
PMID 16940094, PMID 18477269, PMID 20701619, PMID 27029851, PMID 32546269